亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial

医学 放射治疗 不利影响 滤泡性淋巴瘤 临床终点 随机对照试验 淋巴瘤 外科 内科学
作者
Peter Hoskin,B. Popova,Oliver Schofield,Caroline Brammer,Martin Robinson,Adrian Murray Brunt,Krishnaswamy Madhavan,Tim Illidge,Eve Gallop‐Evans,Isabel Syndikus,Laura Clifton‐Hadley,Amy A. Kirkwood
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (3): 332-340 被引量:104
标识
DOI:10.1016/s1470-2045(20)30686-0
摘要

Background The optimal radiotherapy dose for indolent non-Hodgkin lymphoma is uncertain. We aimed to compare 24 Gy in 12 fractions (representing the standard of care) with 4 Gy in two fractions (low-dose radiation). Methods FoRT (Follicular Radiotherapy Trial) is a randomised, multicentre, phase 3, non-inferiority trial at 43 study centres in the UK. We enrolled patients (aged >18 years) with indolent non-Hodgkin lymphoma who had histological confirmation of follicular lymphoma or marginal zone lymphoma requiring radical or palliative radiotherapy. No limit on performance status was stipulated, and previous chemotherapy or radiotherapy to another site was permitted. Radiotherapy target sites were randomly allocated (1:1) either 24 Gy in 12 fractions or 4 Gy in two fractions using minimisation and stratified by histology, treatment intent, and study centre. Randomisation was centralised through the Cancer Research UK and University College London Cancer Trials Centre. Patients, treating clinicians, and investigators were not masked to random assignments. The primary endpoint was time to local progression in the irradiated volume based on clinical and radiological evaluation and analysed on an intention-to-treat basis. The non-inferiority threshold aimed to exclude the chance that 4 Gy was more than 10% inferior to 24 Gy in terms of local control at 2 years (HR 1·37). Safety (in terms of adverse events) was analysed in patients who received any radiotherapy and who returned an adverse event form. FoRT is registered with ClinicalTrials.gov, NCT00310167, and the ISRCTN Registry, ISRCTN65687530, and this report represents the long-term follow-up. Findings Between April 7, 2006, and June 8, 2011, 614 target sites in 548 patients were randomly assigned either 24 Gy in 12 fractions (n=299) or 4 Gy in two fractions (n=315). At a median follow-up of 73·8 months (IQR 61·9–88·0), 117 local progression events were recorded, 27 in the 24 Gy group and 90 in the 4 Gy group. The 2-year local progression-free rate was 94·1% (95% CI 90·6–96·4) after 24 Gy and 79·8% (74·8–83·9) after 4 Gy; corresponding rates at 5 years were 89·9% (85·5–93·1) after 24 Gy and 70·4% (64·7–75·4) after 4 Gy (hazard ratio 3·46, 95% CI 2·25–5·33; p<0·0001). The difference at 2 years remains outside the non-inferiority margin of 10% at −13·0% (95% CI −21·7 to −6·9). The most common events at week 12 were alopecia (19 [7%] of 287 sites with 24 Gy vs six [2%] of 301 sites with 4 Gy), dry mouth (11 [4%] vs five [2%]), fatigue (seven [2%] vs five [2%]), mucositis (seven [2%] vs three [1%]), and pain (seven [2%] vs two [1%]). No treatment-related deaths were reported. Interpretation Our findings at 5 years show that the optimal radiotherapy dose for indolent lymphoma is 24 Gy in 12 fractions when durable local control is the aim of treatment. Funding Cancer Research UK.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甜甜的悲发布了新的文献求助10
刚刚
甜甜的悲发布了新的文献求助10
1秒前
甜甜的悲发布了新的文献求助10
1秒前
甜甜的悲发布了新的文献求助10
1秒前
甜甜的悲发布了新的文献求助10
1秒前
甜甜的悲发布了新的文献求助10
1秒前
甜甜的悲发布了新的文献求助10
1秒前
甜甜的悲发布了新的文献求助10
1秒前
甜甜的悲发布了新的文献求助10
1秒前
丘比特的应助被anew_tape采纳,获得10
10秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
12秒前
科目三的应助被科研通管家采纳,获得10
12秒前
传奇3的应助被科研通管家采纳,获得10
12秒前
null的应助被科研通管家采纳,获得20
12秒前
null的应助被科研通管家采纳,获得20
12秒前
淡然海完成签到,获得积分10
15秒前
17秒前
17秒前
19秒前
21秒前
闪闪雍完成签到,获得积分10
23秒前
26秒前
26秒前
ccc完成签到,获得积分10
29秒前
好好学习发布了新的文献求助10
30秒前
SciGPT的应助被李糯的饺子采纳,获得10
41秒前
好好学习完成签到,获得积分10
41秒前
俭朴的鸿完成签到,获得积分10
43秒前
49秒前
elfriede完成签到 ,获得积分10
51秒前
沉默的樱完成签到,获得积分10
55秒前
悦耳安萱完成签到 ,获得积分10
59秒前
孙元完成签到 ,获得积分10
1分钟前
仰勒完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
1分钟前
开心的筮完成签到,获得积分10
1分钟前
1分钟前
lb001完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667